Atea Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2021 Annual Meeting of Stockholders held by Atea Pharmaceuticals, Inc. on June 18, 2021. The company is incorporated in Delaware and its common stock trades on The Nasdaq Global Select Market under the symbol AVIR. The filing was signed on June 21, 2021.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
A total of 54,426,212 shares were present at the meeting, representing approximately 65.78% of outstanding common stock as of the April 23, 2021 record date. The following proposals were approved:
- Election of Directors (Item 1): Jean-Pierre Sommadossi, Ph.D., and Franklin Berger were elected as Class I Directors to serve until the 2024 Annual Meeting.
- Ratification of Auditors (Item 2): The appointment of KPMG LLP as the independent registered public accounting firm for the year ending December 31, 2021, was ratified.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the election of Jean-Pierre Sommadossi, Ph.D., and Franklin Berger to the Board of Directors.
- Confirm the ratification of KPMG LLP as the independent auditor for fiscal year 2021.
- Note that 272,852 broker non-votes were recorded for the director elections.
- Review the Definitive Proxy Statement filed on April 29, 2021, for detailed background on the proposals.